Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Vyne Therapeutics Inc VYNE

Healthcare
VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:VYNE)

VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire November 7, 2024

VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor

GlobeNewswire September 12, 2024

VYNE Therapeutics to Participate in September Investor Conferences

GlobeNewswire September 3, 2024

VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire August 14, 2024

VYNE Therapeutics Announces Granting of Composition of Matter Patent for VYN202, a Novel BD2-Selective BET Inhibitor

GlobeNewswire July 16, 2024

VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development

GlobeNewswire July 9, 2024

VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum

GlobeNewswire June 26, 2024

VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202

GlobeNewswire June 13, 2024

VYNE Therapeutics Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201

GlobeNewswire June 5, 2024
View More News ››

Opinion & Analysis (NDAQ:VYNE)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:VYNE)

VYNE Therapeutics Inc. (NASDAQ:VYNE): Unlocking the Potentia

http://beyondspx.com/2024/07/31/vyne-therapeutics-inc-nasdaqvyne-unlocking-the-potential-of-bet-inhibition-in-immuno-inflammatory...
MikeTester - August 2, 2024

VYNE......no volume

Just a big "nothing burger"
Iseneschal - February 15, 2023

VYNE...... NR

On watch at $4 No position
Iseneschal - February 15, 2023
View more Bullboard ››

NurExone Biologic Inc.

NurExone Biologic Inc.

NurExone Biologic Inc. is a biopharmaceutical company. The Company is developing and commercializing an exosome therapy ...
View More »